Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CureVac (CVAC) EBIT Margin (2019 - 2025)

Historic EBIT Margin for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to 573.04%.

  • CureVac's EBIT Margin rose 4984500.0% to 573.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 232.21%, marking a year-over-year increase of 2068700.0%. This contributed to the annual value of 33.2% for FY2024, which is 5432800.0% up from last year.
  • As of Q3 2025, CureVac's EBIT Margin stood at 573.04%, which was up 4984500.0% from 4959.52% recorded in Q2 2025.
  • CureVac's 5-year EBIT Margin high stood at 573.04% for Q3 2025, and its period low was 6128.44% during Q1 2025.
  • Its 5-year average for EBIT Margin is 975.8%, with a median of 488.4% in 2021.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 10922200bps in 2022, then plummeted by -55358900bps in 2025.
  • CureVac's EBIT Margin (Quarter) stood at 13.35% in 2021, then crashed by -7679bps to 1038.46% in 2022, then soared by 63bps to 389.38% in 2023, then rose by 22bps to 302.07% in 2024, then skyrocketed by 290bps to 573.04% in 2025.
  • Its EBIT Margin stands at 573.04% for Q3 2025, versus 4959.52% for Q2 2025 and 6128.44% for Q1 2025.